Your Cells Make Their Own Antibiotics: A Hidden Layer of Innate Immunity

Redacción HC
17/04/2025

In a groundbreaking study published in Nature (March 2025), researchers have unveiled a previously unknown immune mechanism within human cells. Long considered a simple cellular garbage disposal, the proteasome—a protein-degrading complex—has now been shown to produce natural antibiotic peptides that directly fight bacterial infections.

Titled “Cell-autonomous innate immunity by proteasome-derived defence peptides,” the study sheds light on how cells generate their own defense weapons, independently of the adaptive immune system. The implications are profound: from understanding basic biology to combating the global threat of antibiotic resistance, this discovery opens up an entirely new chapter in immunology.

Beyond Waste Management: The Proteasome as a Bacterial Assassin

A New Role for a Familiar Structure

Traditionally, the proteasome has been seen as a vital component of cellular quality control, breaking down misfolded or damaged proteins into small peptide fragments. Some of these fragments are presented to the immune system via MHC class I molecules, enabling adaptive immune recognition of intracellular threats.

But the question remained: Could the proteasome's peptides also play a direct role in innate immunity?

This study answers with a resounding yes. Researchers from the Weizmann Institute of Science, Bar-Ilan University, and the University of Illinois demonstrated that some peptides produced by the proteasome act as antimicrobial agents, directly disrupting bacterial membranes and reducing infection loads inside the cell—without the need for antibodies or T-cells.

High-Tech Methods Reveal a Low-Key Defense Arsenal

Cellular Experiments, Simulations, and Animal Models

To investigate this hidden mechanism, scientists used a combination of:

1. In vitro infection assays with human lung cells (A549), exposing them to Salmonella typhimurium. They found that inhibiting the proteasome using bortezomib led to a significant increase in bacterial survival.
2. Computational simulations, where they mapped over 300,000 potential proteasome-derived defence peptides (PDDPs) based on human protein sequences and predicted antimicrobial properties.
3. In vivo testing in mouse models of pneumonia and sepsis, showing that synthetic PDDPs were as effective as conventional antibiotics at reducing bacterial burden.

Not All Trash Is Useless: What Makes These Peptides Special?

Antibacterial Action Without Collateral Damage

The identified PDDPs shared key features with known antimicrobial peptides:

• Cationic charge (which allows them to bind negatively charged bacterial membranes).
• Amphipathic structure (enabling membrane disruption).
• Low toxicity to human cells, as confirmed by histological analyses in treated animals.

These peptides acted like precision-guided missiles, destroying bacterial cells from within—without harming the host tissue.

Further experiments revealed that after infection, the cell increases production of a specific proteasome subunit (PSME3) and shifts to a trypsin-like cleavage pattern, increasing the output of PDDPs. In essence, the cell adjusts its waste-processing machinery to generate targeted microbial defenses during an infection.

Implications for Medicine: The Antibiotics Were Inside Us All Along

From Basic Discovery to Therapeutic Potential

This revelation is not just academic. It comes at a time when antibiotic resistance threatens public health globally, especially in low-resource settings.

Researchers suggest multiple real-world applications:

• Next-generation antibiotics: PDDPs can be synthesized, optimized, or engineered to serve as natural antimicrobials, with distinct mechanisms from existing drugs.
• Therapeutic adjuvants: Boosting proteasomal activity—or mimicking the conditions that lead to PDDP production—might enhance natural immunity.
• Diagnostics: Specific PDDPs could become biomarkers for cellular immune activity, useful in infection monitoring or immune profiling.

A Call for Further Research and Innovation

The authors recommend:

1. Clinical studies to determine natural levels of PDDP production during infections in humans.
2. Toxicological assessments in complex tissue environments or human organoids.
3. Development of delivery systems—like nanoparticles—to target PDDPs to infection sites.

Given the ubiquity of the proteasome in all cells, the potential to harness internal defenses could revolutionize how we treat infections, especially in the face of drug-resistant pathogens.

Conclusion: The Secret Antibiotics Hidden in Your Cells

This study redefines the role of a well-known cellular machine. The proteasome, long thought to simply recycle waste, is now understood to be an active participant in innate immunity, producing a vast arsenal of defense peptides capable of directly killing bacteria.

For immunologists, it’s a paradigm shift. For clinicians, it’s a promising path forward. And for all of us, it’s a powerful reminder that our cells are smarter and more self-sufficient than we thought.

Topics of interest

Health